On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.

Using recombinant protein technology and a new self-developed MA105 adjuvant system, Maxvax has independently developed the Herpes Zoster Vaccine. It is the first innovative vaccine with a complex adjuvant system that has entered the Phase II clinical study in China, owning independent intellectual property rights and a controllable supply chain. This vaccine can promote high-level humoral and cellular immune responses against the varicella-zoster virus and prevent the onset of herpes zoster. The preliminary safety observation results of the Phase I clinical study have shown that this product has good safety and tolerability. The Phase II clinical study will further expand the enrollment, so as to evaluate the safety, immunogenicity and immune persistence, and provide data support for the design of the Phase III clinical study.

According to Dr. Chen, CEO and founder of Maxvax, this pipeline entering Phase II clinical study is another milestone for the Company's adjuvant platform to carry out the development of major innovative vaccines and to provide solutions for the prevention and control of major diseases and infectious diseases. In addition to the traditional aluminum adjuvant, only six new adjuvants have been approved for marketing worldwide, but all are developed by foreign pharmaceutical companies. China's vaccine industry has been challenged by the technology bottleneck in the new adjuvant. Maxvax successfully initiated the Phase II clinical study of the Recombinant Herpes Zoster Vaccine using the MA105 adjuvant system, indicating that this vaccine with a new adjuvant system has shown good safety in the Phase I clinical study and the Company takes a solid step forward in response to the 14th Five-Year Plan of the State to focus on dealing with the technology bottleneck in the new adjuvant. More immunogenicity and safety data will be obtained in the Phase II clinical study of this product, and we have the confidence to develop safe and effective vaccines, so as to provide solutions to global public health challenges.

About Maxvax

Maxvax is an international biopharmaceutical enterprise dedicated to the R&D, production and commercialization of innovative vaccines and new adjuvants. It has R&D centers and business teams in Chengdu, Shanghai and Hangzhou, China as well as Seattle, the United States. The industrialization base for human vaccines is located in the Lin-gang Special Area of Shanghai, with more than 300 employees. Maxvax Biotech focuses on the key and urgently required vaccines in clinical practice including preventive vaccines, therapeutic vaccines and tumor vaccines and has laid out diversified product R&D pipelines. At present, its first batch of two pipeline products has entered the clinical study stage.